Nothing Special   »   [go: up one dir, main page]

Phillips et al., 1987 - Google Patents

In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.

Phillips et al., 1987

View PDF
Document ID
10271445025810229779
Author
Phillips J
Gemlo B
Myers W
Rayner A
Lanier L
Publication year
Publication venue
Journal of Clinical Oncology

External Links

Snippet

Patients with advanced metastatic cancer were given combined autologous lymphokine activated killer (LAK) cell and recombinant interleukin-2 (rIL-2) therapy on a National Cancer Institute extramural phase II trial. Systemic administration of rIL-2 resulted in pronounced …
Continue reading at www.researchgate.net (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells

Similar Documents

Publication Publication Date Title
Phillips et al. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
Phillips et al. Natural killer cells activated in a human mixed lymphocyte response culture identified by expression of Leu-11 and class II histocompatibility antigens.
Schäkel et al. A novel dendritic cell population in human blood: one‐step immunomagnetic isolation by a specific mAb (M‐DC8) and in vitro priming of cytotoxic T lymphocytes
Phillips et al. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis.
EP3134514B1 (en) Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
Reittie et al. Endogenously generated activated killer cells circulate after autologous and allogeneic marrow transplantation but not after chemotherapy
Schmidt-Wolf et al. Activated T cells and cytokine-induced CD3+ CD56+ killer cells
Ioannides et al. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites
McMannis et al. In vivo effects of recombinant IL-2. I. Isolation of circulating Leu-19+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2.
Ochoa et al. Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets
Rabinowich et al. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells
Albi et al. Natural killer (NK)-cell function and antileukemic activity of a large population of CD3+/CD8+ T cells expressing NK receptors for major histocompatibility complex class I after" three-loci" HLA-incompatible bone marrow transplantation
Roberts et al. Separation and functional studies of the human lymphokine-activated killer cell
CN111566201A (en) Methods of transducing cells using viral vectors for expression of Chimeric Antigen Receptors (CARs) or transgenic T Cell Receptors (TCRs)
Schmidt et al. Enhancement of natural killer function through activation of the T11 E rosette receptor.
Ellenhorn et al. Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.
Dianzani et al. CD8+ CD11b+ peripheral blood T lymphocytes contain lymphokine‐activated killer cell precursors
Sosman et al. Specific recognition of human leukemic cells by allogeneic T cell lines
Braakman et al. Expression of CD45 isoforms by fresh and activated human γδ T lymphocytes and natural killer cells
Adler et al. Interleukin-2 induction of lymphokine-activated killer (LAK) activity in the peripheral blood and bone marrow of acute leukemia patients: II. Feasibility of LAK generation in children with active disease and in remission
Phillips et al. Acquisition of non-MHC restricted cytotoxic function by IL 2 activated thymocytes with an" immature" antigenic phenotype.
Massaro et al. Solid-phase anti-CD3 antibody activation of murine tumor-infiltrating lymphocytes
Van de Griend et al. In vitro expansion and analysis of cloned cytotoxic T cells derived from patients with chronic T gamma lymphoproliferative disorders
Morishita et al. Antigen-specific functions of a CD4+ subset of human T lymphocytes with granular morphology.
Montagna et al. Identification of HLA-unrestricted CD8+/CD28-cytotoxic T-cell clones specific for leukemic blasts in children with acute leukemia